ClinicalTrials.gg
Status unknownNCT05151705Updated Dec 9, 2021

A Trial of HR17031 Injection With Hepatic Insufficiency

A Phase 1 interventional study of HR17031 injection and HR17031 injection in Improved Glycemic Control in Patients With Type 2 Diabetes, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-09.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd. — 8 open to participants now, 11 under way, 4 of them phase 3. Diabetes Mellitus, Type 2 · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
58th of 81
24 · median 80
Started
2021
with 7 others
Phase 1
48 of 81
4 open now
Registered
39th of 81
by date

Among the 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd., this one is the 58th largest by planned enrollment, is one of 8 that started in 2021, is one of 48 in phase 1, and was the 39th registered.

Diabetes Mellitus, Type 2

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

8 of the 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This study used a single-dose, open design to compare the pharmacokinetics of subjects with mild and moderate liver impairment and subjects with normal liver function.

03

Conditions studied

  • Improved Glycemic Control in Patients With Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed the before the test, and fully understood the test content, process and possible adverse reactions; And able to complete the research according to the requirements of the test protocol;
  2. Subject (including partner) is willing to voluntarily take effective measures within 10 weeks from screening to the last study drug administration. For specific contraceptive measures, see Appendix 1;
  3. Age 18-65 (including threshold), male and female;
  4. The weight of male subjects should not be less than 50 kg, and that of female subjects should not be less than 45 kg. (BMI) : 18\~32 kg/m2 (including critical value);
  5. For subjects with normal liver function, normal or abnormal clinical laboratory tests (blood routine, blood biochemistry, urine routine, coagulation function) have no clinical significance;
  6. Subjects with normal liver function: no previous serious primary diseases of important organs, including but not limited to gastrointestinal, respiratory, kidney, liver, nervous, blood, endocrine, tumor, immune, mental or cardiovascular diseases.

    For subjects with impaired liver function, the following inclusion criteria should also be met:

  7. Those who have not taken medication within 4 weeks prior to screening, or who require long-term treatment for liver damage and/or other comorbidities, have taken stable medication for at least 4 weeks;
  8. Patients with grade A or B hepatic dysfunction resulting from previous primary liver disease.

Exclusion criteria

Exclusion Criteria:

  1. Allergic disposition, or known or suspected allergy to any of the ingredients in the study drug;
  2. Smoked more than 5 cigarettes per day on average within 3 months before screening;
  3. Average daily alcohol intake in the 3 months prior to screening exceeds the following criteria: 15g (e.g., 145 mL wine, 497 mL beer or 43 mL low-alcohol liquor) for women and 25g (e.g., 290 mL wine, 994 mL beer or 86mL low-alcohol liquor) for men;
  4. A history of drug abuse within 3 months prior to the screening period;
  5. Those who donated blood or lost blood ≥400 mL or received blood transfusion within 3 months prior to screening;
  6. Major surgery or surgical incision not completely healed within 6 months prior to screening;
  7. Taking Chinese herbal medicine within 2 weeks before administration;
  8. Have a malignant tumor, or have a history of malignant tumor in the 5 years prior to screening (excluding treated skin non-melanoma with no signs of recurrence, and excised cervical intraepithelial neoplasia);
  9. Systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg at screening time;
  10. Female subjects are lactating or have positive serum pregnancy results during the screening period or during the test;
  11. For subjects with normal liver function: participants in clinical trials of any drug or medical device within 3 months prior to screening; For subjects with impaired liver function: participants in clinical trials of any drug or medical device within 1 month prior to screening;
  12. Patients whose abnormality is (e.g., tachycardia/bradycardia requiring medical treatment, degree II-III ATrioventricular block, or prolonged interval (males ≥470 ms, females ≥480 ms) (corrected according to Fridericia's formula) and determined by clinicians to be unsuitable for this study;
  13. (CLcr, calculated by Cockcroft-Gault formula, Appendix III) ≤60 mL/min;
  14. Subjects with normal liver function: those who are positive for surface antigen, antibody or hepatitis C core antigen, antibody or syphilis antibody screened are excluded;
  15. Screening for positive urine drugs (morphine, cannabis);
  16. Within 1 day before administration, those who have eaten any food or drink containing alcohol (or positive breath test for alcohol), grapefruit juice/grapefruit juice, methylxanthine (such as coffee, tea, cola, chocolate, energy drink), strenuous exercise or other factors affecting drug absorption, distribution, metabolism, excretion, etc.;
  17. Patients who are expected to be prone to surgery or hospitalization during the study period;
  18. Any factors that the investigator considers inappropriate for participation in this study.

    Supplementary exclusion criteria for subjects with liver function impairment (exclusion if meeting 1 of these criteria) :

  19. History of liver transplantation;
  20. Subjects with liver failure or cirrhosis with hepatic encephalopathy, hepatocellular carcinoma, esophageal and gastric variceal hemorrhage and other complications deemed unsuitable for the study by the investigator;
  21. In addition to the primary liver disease itself, has a history of any serious illness, or history of researchers think that may affect the test results and/or anomalies have clinical significance of clinical laboratory tests, including but not limited to the circulatory system, endocrine system, nervous system, digestive system, urinary system, or blood, immune, spirit and metabolic disease.
  22. HIV antibody screening positive; If syphilis antibody is positive, rapid plasma rereaction test (RPR) should be added. If RPR is positive at the same time, it should be excluded.
  23. Alpha-fetoprotein > 50 ng/mL; Or (ANC) ≥0.75×109/L (1,500/mm3); Or ≤7.0 g/dL (90 g/L); Or and AST ≥10 times the (ULN) were excluded.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Treatment group A: HR17031 injection

    Drug: HR17031 injection

  • Experimental
    Treatment group B: HR17031 injection

    Drug: HR17031 injection

  • Experimental
    Treatment group C: HR17031 injection

    Drug: HR17031 injection

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics parameters of INS068 and SHR20004: Cmax

    Time frame: Based on pre-dose, 2-96 hours post-dose sampling times

  2. Pharmacokinetics parameters of INS068 and SHR20004: AUC0-t

    Time frame: Based on pre-dose, 2-96 hours post-dose sampling times

  3. Pharmacokinetics parameters of INS068 and SHR20004: AUC0-inf

    Time frame: Based on pre-dose, 2-96 hours post-dose sampling times

Secondary outcomes

  1. Pharmacokinetics parameters of INS068 and SHR20004: Tmax

    Time frame: Based on pre-dose, 2-96 hours post-dose sampling times

  2. Pharmacokinetics parameters of INS068 and SHR20004: T1/2

    Time frame: Based on pre-dose, 2-96 hours post-dose sampling times

  3. Pharmacokinetics parameters of INS068 and SHR20004: CL/F

    Time frame: Based on pre-dose, 2-96 hours post-dose sampling times

  4. Pharmacokinetics parameters of INS068 and SHR20004: Vz/F

    Time frame: Based on pre-dose, 2-96 hours post-dose sampling times

  5. Binding rate of plasma protein of INS068 in serum and SHR20004 in plasma(fu)

    Time frame: Based on pre-dose, 2-96 hours post-dose sampling times

  6. The incidence and severity of adverse events/serious adverse events

    Time frame: Based on pre-dose, 2-96 hours post-dose sampling times

  7. Pharmacodynamic:Serum c-peptide

    Time frame: Based on pre-dose, 8-24 hours post-dose sampling times

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2021; primary completion for Jun 2022, 5 months later.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's planned 5 months is close to that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2021
First posted
Dec 9, 2021
StartEst.
Dec 20, 2021
Primary completionEst.
Jun 15, 2022
CompletionEst.
Jun 30, 2022
Last update
Dec 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05151705
Responsible party
Sponsor
First posted
Dec 9, 2021
Start date
Dec 20, 2021 (estimated)
Primary completion
Jun 15, 2022 (estimated)
Completion
Jun 30, 2022 (estimated)
Last update
Dec 9, 2021

Study contacts

Sheng Feng, Ph.D.
Contact
Sheng.feng@hengrui.com
13817253036
Yuxiong Gao, Ph.D.
Contact
gaoyu.xiong@hengrui.cn
19821262236

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HR17031

Start the discussion